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Background: Adsorptive granulocyte and monocyte apheresis (GMA) with an Adacolumn in patients with
ulcerative colitis (UC) has been applied as a non-pharmacological treatment strategy, but the efficacy has been
encouraging as well as discouraging, depending on patients’ demography at entry. In this study, we looked for
predictive factors for clinical response to GMA in patients with UC.
Methods: In a retrospective setting, 43 outpatients who had been treated with GMA for active UC were evaluated.
Patients were divided into remission group and non-remission group based on Lichtiger’s clinical activity index
(CAI) before and after 10, once a week GMA sessions. The efficacy was analysed in relation to patients’
demographic variables. To determine predictive factors that closely related to the response to GMA, receiver
operating characteristic (ROC) curve, and multiple logistic regression analyses were applied.
Results: After 10 GMA sessions, the overall clinical remission rate (CAI < 4) was 53.5%. Multiple logistic regression
and ROC analyses showed that the interval between relapse and the first GMA session was a significant and
independent predictive factor for clinical response to GMA (P = 0.016); the clinical response was better in patients
who received GMA immediately after a relapse and vice versa. Likewise, univariate analyses showed that, the
duration of UC (P = 0.036) and the cumulative prednisolone (PSL) dose (P = 0.006) before the first GMA session were
significantly greater in the GMA non-responder group as compared with the responder group. Additionally, a lower
white blood cell (WBC) count at first GMA session was related to clinical response to GMA (P = 0.032).
Conclusions: In this study, patients with a short duration of UC and low cumulative PSL dose seemed to respond
well to GMA. However, we found that the best responders were patients who received GMA immediately after a
clinical relapse. Additionally, GMA was effective in patients with low WBC count at the first GMA session. The
findings of this study should spare medical cost and reduce morbidity time for many patients, relevant for decision
making in clinical settings.
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Ulcerative colitis (UC) is one of the two major forms of
the idiopathic inflammatory bowel disease (IBD), which
afflicts millions of individuals throughout the world with
symptoms that impair performance and quality of life
[1,2]. Although the aetiology of UC is still not fully under-
stood, elevated and activated myeloid lineage leucocytes
(granulocytes and monocytes) potentially are significant
factors in the exacerbation and the perpetuation of IBD
[1,3-6] by releasing inflammatory cytokines [6,7]. Accor-
dingly, in recent years, selective depletion of myeloid
lineage leucocytes by adsorptive granulocyte and mono-
cyte apheresis (GMA) with an Adacolumn has been
applied as a non-pharmacologic treatment strategy in
patients with UC [6-15]. However, the efficacy outcomes
have been promising [6-14] as well as disappointing
[15], with evidence that demographic variables of the
patients at entry might indicate response to GMA
[16]. In line with this assertion, even in Japan where
GMA is most widely used, the popular opinion is that
patients’ disease activity level, location and duration
of disease, the extent of mucosal damage, hitherto
response to conventional medications, and other
known causes of refractoriness like cytomegalovirus
infection should be taken into consideration to select
patients for GMA therapy [16-18].
However, until now, it has been difficult to select the
right patients for therapeutic GMA due to lack of
established biomarkers of clinical response to this
non-pharmacologic treatment intervention. The routinely
applied weekly GMA is thought to be inadequate for effi-
cient depletion of activated myeloid lineage leucocytes in
patients with severe disease. Based on this perception,
Sakuraba, et al. [6] have reported that GMA at 2 sessions
per week was better than one session per week both with
respect to efficacy rate and time to the disappearance of
UC symptoms. Likewise, Yoshimura, et al. [19] increased
the processed blood volume per session and reported
significantly better efficacy rate. Therefore, there have
been various attempts to improve the cost effective-
ness of GMA. In this study, we were interested to
identify markers of clinical response to GMA. Based
on this intention, we looked at clinical response and
patients’ demographic variables. The 43 patients we
included in this study had been treated with GMA,
and were reviewed in a retrospective setting.
Methods
Ethical considerations
In Japan, GMA with the Adacolumn is a Ministry of
Health approved therapeutic option for patients with
active IBD. Accordingly, this method is a standard
therapy at our institute, where all included patients had
been treated prior to this retrospective investigation bythe physicians who undertook this retrospective study.
However, prior to treatment, physicians ask the patients to
choose either GMA or conventional pharmacologics, and
at that time, patients are briefed on the nature of the
procedures involved with respect to GMA. Additionally,
our investigation protocol was reviewed and approved by
the Ethics Committee of Hyogo Medical College Hospital
(the study site). During the active treatment, adherence
was made to the Principle of Good Clinical Practice
at all times.
Study design and aims
This was a retrospective single centre study conducted
at the Hyogo College of Medicine in Japan. The eligible
patients had been treated with GMA between April
2007 and March 2010 at this centre. In our database, we
selected outpatients who were on daily low-dose pred-
nisolone (PSL), average 17.2 mg/day including topical
steroids, and could continue as concomitant medication
during the GMA course. PSL administration had started
well in advance of receiving GMA. The purpose of the
study was to identify background factors as markers of
clinical response to GMA. With this in mind, we fac-
tored patients’ demographic variables and their clinical
response to GMA in our analyses. Additionally, we
aimed to assess the position of GMA as an add-on or as
a mono-therapy in patients with active UC, and this was
one reason for selecting patients who had not achieved
remission while receiving PSL.
Patient selection and efficacy assessments
Forty-three outpatients with active UC had received 10
consecutive weekly GMA, at one session per week as
shown in Figure 1. Patients’ main demographic variables
are presented in Table 1. Among the 43 patients, 15
were male, and 28 were female, average age 41.5 years,
range 18–71 years, all with a definitive diagnosis of UC.
Among the 43 patients, UC was steroid-refractory in 3
patients (7.0%), steroid-dependent in 25 patients (58.1%),
and undetermined in 3 patients. Patients were classified
as steroid-refractory or steroid-dependent according to
Ogata, et al. [20]. Steroid-refractory was defined as lack
of response to an oral dose of more 30 mg/day PSL over
at last 2 weeks, while steroid-dependent was defined as
either chronically active UC for more than 6 months or
with frequent recurrence (more than once a year, or three
times or more every two years) regardless of medication.
Further, patients with clinical activity index (CAI) >5 were
classified as having active disease. CAI ≥12, 7–11, and ≤6
were defined as severe, moderate and mild, respectively,
while CAI ≤4 meant clinical remission [21]. Patients with
severe, moderate and mild UC were 16.3% (7 of 43), 72.1%
(31 of 43) and 11.6% (5 of 43). Among the 43 patients, 31
(72.1%) were receiving PSL as described above, and 10
Figure 1 Treatment of patients and summary of the clinical outcomes. GMA, adsorptive granulocyte and monocyte apheresis; PSL,
prednisolone; AZA, azathioprine; 5-ASA, 5-aminosalicylic acid.
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medication. None of the included patients had received
tacrolimus, cyclosporine or infliximab prior to GMA.
Mucosal UC disease activity at entry and following a
course of GMA was evaluated by using the endoscopic
index (EI) described by Rachmilewitz [22]. Mucosal hea-
ling was defined as EI < 3. The 43 patients were dividedTable 1 Baseline demographic variables of the 43 eligible
patients of this study
Gender (Female/Male) 28/15
Age (year) 41.5 ± 14.9
Duration of UC (year) 7.2 ± 7.0
CAI at 1st GMA (mean ± SD) 9.1 ± 2.2
WBC at 1st GMA (mean ± SD) 8900.8 ± 2436.7





PSL + AZA 0
PSL + 5ASA 21
AZA + 5ASA 3




PSL, prednisolone; UC, ulcerative colitis; CAI, clinical activity index; GMA,
granulocyte and monocte apheresis; SD, standard deviation; 5ASA, 5-aminosalicylic
acid; AZA, azathioprine.into remission group and non-remission group based on
CAI before and after a course of GMA. Additionally,
total white blood cell (WBC) count and C-reactive
protein (CRP) were determined.
GMA procedures
GMA treatment was done with the Adacolumn (JIMRO,
Takasaki, Japan) as previously described [23,24]. Briefly,
the Adacolumn is filled with specially designed cellulose
acetate beads of 2 mm in diameter, which serve as the
column adsorptive leucocytapheresis carriers for FcγR
and complement receptor bearing cells. Therefore, the
carriers selectively adsorb from the blood in the column
most of the granulocytes, monocytes/macrophages and a
significant fraction of platelets; lymphocytes are spared
and subsequently increase [6,7]. The duration of one
GMA session was 60 min, at 30 ml/min. An optimum
dose of sodium heparin (2000units/session) was admi-
nistered during GMA as an anti-coagulant.
Statistics
When appropriate, numerical data are presented as the
mean ± SD values. Comparison of demographic variables
between the remission and the non-remission groups
(see above) was done by using the Mann–Whitney
U-test or the Fisher’s exact test. Multiple logistic
regression was applied to determine markers of response
to GMA (Dr SSAPII for Windows). To determine predic-
tive factors that closely related to the response to GMA,
we used receiver operating characteristic (ROC) curves
with area under the curve (AUC). The ROC curves for the
predictive factors were plotted by using the SPSS for
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lated, and the point with the largest AUC was
defined as the point having the greatest association
with the response to GMA. The best cut-off values
of the predictive factors had a minimum distance
from the upper left corner to the point on the ROC curve,
and were distinguishable between the remission and the
non-remission groups. A P value <0.05 was considered
statistically significant.Results
The clinical outcomes after 10 GMA sessions
Figure 1 shows that after 10, once a week GMA sessions,
the overall remission rate was 53.5% or 23 of 43 patients.
Among the 23 responders, 9 patients (39.1%) had
steroid-free remission. Three of the 43 patients received
≤5 GMA sessions and therefore, 40 of 43 patients
received 10 GMA sessions. The changes in the CAI
score for all 40 patients who received at least 5 GMA
sessions are presented in Figure 2. In the 23 responders,
the average CAI score improved from 8.7 ± 1.8 at
baseline to 3.8 ± 0.7 (P < 0.001). Similarly, the average
EI score (n = 23) was significantly better, 8.5 ± 2.4 vs
1.8 ± 1.9, (P < 0.05), and 56.5% of those who achieved
clinical remission had mucosal healing as well. The daily
PSL dose was significantly tapered from 18.7 ± 14.4 mg/
day at baseline to 5.2 ± 6.1 mg/day (P < 0.05) in responders
after 10 GMA sessions. Colonoscopic finding in 3 typical
responder patients who achieved mucosal healing are
shown in Figure 3, while Figure 4 shows typical colono-
scopic feature of patients who may not benefit from GMA
therapy (see below).Figure 2 The clinical efficacy of GMA based on changes in Lichiger’s
GMA sessions.Predictive factors for response to GMA
We applied multiple logistic regression analysis as well as
univariate analyses to identify markers of clinical response
to GMA (Tables 2, and 3). In univariate analysis, there
was no significant difference in age, gender, extent of col-
itis, CAI score, the daily PSL dose and response to steroids
at baseline between the remission and the non-remission
groups. The cumulative PSL dose before the first GMA
session in the non-remission group was significantly
higher than in the remission group, 939.2 ± 1125.9 mg vs
4578.5 ± 4752.6 mg (P = 0.006). The duration of UC was
significantly shorter in the remission group as compared
with the non-remission group, 6.1 ± 7.3 yr vs 8.6 ± 6.8 yr
(P = 0.036). Likewise the mean interval between relapse
and the first GMA session was significantly shorter in the
remission group as compared with the non-remission
group, 27.7 ± 31.0 days vs 76.2 ± 88.1 days (P = 0.016).
Another variable, which tended to be significantly
different between the remission and the non-remission
groups at baseline was WBC, 8304.1 ± 2432.3/ul vs
9572.9 ± 2283.4/ul, respectively (P = 0.032). Multiple
logistic regression analysis showed that the interval
between relapse and the first GMA session was a sign-
ificant independent predictive factor of response to GMA
(P = 0.016). Therefore, GMA at an early stage following a
clinical relapse is likely to induce remission of an active
UC. Likewise, baseline WBC was a significant independent
predictive factor for response to GMA (P = 0.025).
The cut-off values of the 3 factors that closely related to
GMA efficacy
Figure 5 shows the ROC curve for the 3 factors (the
interval between relapse and the first GMA session,clinical activity index (CAI) evaluated at entry, after 5 and 10
Figure 3 Endoscopic findings in 3 typical responders to GMA. All patients achieved complete remission after weekly GMA sessions. One of
these patients (Figure 3a) with the first UC episode had absence of vascular patterns, spontaneous bleeding, erythema, oedema and friability at
entry. This patient showed an early response to GMA, after receiving just 5 GMA sessions and achieved mucosal healing (MH) a few months later
(Figure 3b). The second patient with steroid-dependent UC had extensive ulcers, oedematous mucosa at entry (Figure 3c). This patient achieved
clinical remission and partial MH after 10 GMA sessions (Figure 3d). The third patient had a short duration of UC and absence of vascular
patterns, spontaneous bleeding, erythema, ulcers and friability at entry (Figure 3e). This patient achieved MH a few months later after 10 GMA
sessions (Figure 3f). These 3 patients had maintained remission at week 54 following the last GMA session.
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dose before the first GMA session) in the remission
group vs the non-remission group. The optimal cut-off
value estimated for these factors that allows for the
distinction of the remission group compared to the non-
remission group was 2735.5 mg, 10160/μL and 49.5 days.
The AUC of the ROC values, the cut-off values, sensiti-
vity and specificity are summarised in Table 4. The AUCFigure 4 Endoscopic findings in a typical non-responder to GMA. At e
tissue at UC lesion sites. GMA was discontinued after 5 sessions as it was julevels, sensitivity and specificity were similar to the
aforementioned factors.
The prognosis of GMA responder patients
Figure 1 shows that after 54 weeks, 11 of the 23 respon-
ders had maintained remission (47.8%). In the relapse
group, the average interval from the last GMA session to
relapse was 4.3 months, range 1–9 months. Prior to thentry, this patient had extensive deep lesions and loss of mucosal
dged futile to administer further GMA sessions to this patient.
Table 2 Comparison of patients’ demographic background in the remission and the non-remission groups by
univariate analysis
Measurements Remission group (n = 23) Non-remission group (n = 20) P-value
Age, year 39.2 ± 13.6 44.1 ± 16.2 ns
CAI score 8.9 ± 2.1 9.3 ± 2.3 ns
Duration of UC (year) 6.1 ± 7.3 8.6 ± 6.8 0.036
Interval between relapse and the 1st GMA (day) 27.7 ± 31.0 76.2 ± 88.1 0.016
PSL at the 1st GMA (mg/day) 18.7 ± 14.4 17.8 ± 10.5 ns
Cumulative PSL dose before 1st GMA (mg) 939.2 ± 1125.9 4578.5 ± 4752.6 0.006
WBC at the 1st GMA (/ul) 8304.1 ± 2432.3 9572.9 ± 2283.4 0.032
Hb at the 1st GMA (g/dl) 12.0 ± 1.7 12.7 ± 2.0 ns
CRP at the 1st GMA (mg/dl) 0.7 ± 1.0 0.7 ± 0.8 ns
CAI, clinical activity index; CRP, C-reactive protein; GMA, granulocyte and monocte apheresis; Hb, haemoglobin; WBC, white blood cell; ns, not significant (p > 0.05).
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rence in entry demographic variables (gender, age, CAI,
EI, concomitant medications, and daily PSL dose, dur-
ation) between the patients who maintained remission
and those who relapsed. However in the remission group,
72.7% or 8 of 11 patients had achieved clinical remission
with mucosal healing after 10 GMA sessions (complete
remission).
Study safety and patient compliance
Forty outpatients were to receive 10 GMA sessions each
and all 40 patients completed their 10 weekly GMA
sessions, compliance was 100%. Likewise, in this study,
no serious adverse event was observed during GMA
sessions. There was no other serious adverse event or
opportunistic infection during our observation time,
even in patients who were on PSL or AZA as concomitant
medication during the course of GMA.
Discussion
Active UC is debilitating, affects function and quality of
life. The chronic nature of the disease means patients
require medications throughout life. Conventional drugs
often cause adverse side effects, adding to the disease
complexity. It would be reasonable to assume that one
major factor for physicians and patients opting for a
non-pharmacological treatment intervention like GMATable 3 The outcomes of multiple logistic regression
analysis for determining predictive factors of clinical








Interval between relapse and
1st GMA
-0.025 0.016 0.976 0.956 0.995
WBC at 1st GMA 0.000 0.025 1.000 0.999 1.000
WBC, white blood cell; GMA, granulocyte and monocte apheresis.is to avoid adverse side effects of drugs. Ideally, physi-
cians and in particular, patients hope treatment to be
safe and effective. However, the reality of clinical prac-
tice would show that any given therapeutic intervention
is effective only in a fraction of patients treated similarly
for the same condition. The size of the responder frac-
tion reflects the efficacy rate. In Japan and Europe,
GMA with an Adacolumn in patients with UC has been
applied as a non-pharmacological treatment strategy,
but hitherto, the efficacy rate has been different, ranging
from an 85% [9,12-14,25] to a statistically insignificant
level [15]. Treatment failure reflects waste of resourcesFigure 5 Receiver operating characteristic (ROC) curves for the
interval between relapse and the first GMA, WBC at the first
GMA and cumulative PSL dose before the first GMA session in
patients with active ulcerative colitis.
Table 4 Sensitivity, specificity, area under the curve (AUC), and confidence interval (CI) in the determination of the
predictive factors of clinical response to GMA in patients with active ulcerative colitis
Measurements Cut-off value Sensitivity (%) Specificity (%) AUC (95%CI)
Cumulative PSL dose up to the 1st GMA session <2735.5 mg 61 95 0.78 (0.62-0.94)
WBC at 1st GMA session <10160/μL 61 85 0.72 (0.56-0.89)
Interval between relapse and 1st GMA session <49.5 days 50 95 0.76 (0.61-0.92)
GMA, granulocyte and monocte apheresis; PSL, prednisolone; WBC, white blood cell.
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patients. However, there is evidence that the clinical
response to GMA is dictated by patients’ demographic
variables at baseline [26,27] which should be evaluated.
With this background in mind, in this study, we looked
for predictive factors, which could guide us to select
future patients who are most likely to respond to GMA.
The outcome of the present investigation might be sum-
marized as follows. Forty-three outpatients who had
received consecutive weekly GMA at one session per week,
up to 10 sessions for an active UC were retrospectively
reviewed. All 43 patients had active disease in spite of
receiving conventional medications, the majority on PSL.
At the assessment time point, the patients could be divided
into remission group and non-remission group. During
GMA therapy, the PSL dose was tapered and many respon-
ders became steroid free. Typically, the non-responders had
extensive deep ulcers with near total loss of the mucosal
tissue at the affected sites or had a long duration of UC and
exposure to multiple conventional medications. Further,
almost all patients who maintained their clinical remission
for 54 weeks had achieved mucosal healing during the
course of GMA therapy. Therefore, mucosal healing was a
predictive factor for better prognosis [28-30]. Our search
for predictive factors of clinical response to GMA showed
that at baseline, the interval between relapse and the first
GMA session was significantly shorter in the remission
group as compared with the non-remission group.
Additionally, the cumulative PSL dose before the first
GMA session was a significant independent factor, and a
high cumulative PSL dose appeared to negatively impact
the efficacy of GMA. The application of logistic regression
analyses indicated that GMA at an early stage following a
clinical relapse was likely to induce remission of an active
UC. Another significant predictive factor was total WBC at
baseline. However, the percentage of granulocyte in WBC
had increased in all patients (data not shown).
The publication of the first clinical experience with
GMA in patients with UC by Shimoyama, et al. [31]
generated significant interest in this non-pharmacological
treatment intervention for patients with inflammatory
diseases associated with activated myeloid lineage leuco-
cytes [5-19,23-27,31-38]. However, as already mentioned,
there is no shortage of contrasting efficacy outcome
reports in the literature. In 2004, Suzuki, et al. [9] reportedan 85% efficacy rate or 17 of 20 patients they treated with
GMA as the first line medication. Then a controlled trial
by Sands, et al. [15] reported no statistically significant
difference between the sham arm and the GMA arm. The
patients included in the latter study had a very different
demography, had not responded to conventional medica-
tions. In contrast, all of the patients in Suzuki’s study were
steroid naïve, most with a short UC duration and only
needed first line medication [9,12]. Suzuki, et al.9 reported
that the only 3 GMA non-responders in that study had
defective mucosal tissue and deep ulcers. In a subsequent
study, Suzuki, et al. [27] reported that all patients
with a short duration of UC (about 3 months), and
first episode cases readily responded to GMA, while
all of the 8 GMA non-responders in that study had a
very long duration of UC together with a long history
of exposure to multiple conventional medications. The
observations by Suzuki, et al. [9,27] were independently
confirmed by Tanaka and colleagues in much larger
cohorts of UC patients [16,17,25].
In the present study, the frequency of GMA was one ses-
sion per week at 30 mL/min for 60 min. This is equivalent
to 1800 mL of processed blood volume per GMA session.
This treatment protocol might be inadequate as Sakuraba,
et al. [9] found that 2 GMA sessions per week produced
significantly higher efficacy rate in a shorter time as com-
pared with one session per week. Similarly, Yoshimura,
et al. [19] reported that more than 3000 mL of processed
blood volume per GMA session was significantly more
effective than routinely applied 1800 mL per session.
Additionally, our experience suggests that unlike drug
based medication, GMA demands operational skills,
and maintenance of a steady blood flow.
Conclusions
In our IBD centre, GMA is very much favoured by
patients for its good safety profile. However, the clinical
efficacy of GMA has been encouraging as well as disap-
pointing depending on the baseline demographic features
of the treated patients. Patients with a short duration of
UC responded better and faster to GMA as compared
with patients with a long duration of UC. However, we
found that the best responders to GMA were patients
who received GMA immediately after a relapse. Accor-
dingly, the interval between the clinical relapse and the
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clinical response to GMA. This indicated that GMA
should be effective as a mono-therapy if applied soon
following a UC episode. Additionally, patients with active
UC and a long history of exposure to corticosteroids may
not respond well to GMA. Other independent studies
have reported that steroid naïve and patients with the first
UC episode as the best responders to GMA, while patients
with deep ulcers and extensive loss of the mucosal tissue
at the lesion sites or patients with a long duration of UC
and exposure to multiple drugs as poor responders. The
bottom line might be that GMA should be applied before
patients become refractory to the currently used drugs.
Potentially, the information in this article should spare
medical cost and reduce morbidity time for many patients,
relevant for decision making in clinical settings.
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